紫杉醇脂质体联合卡铂治疗中晚期卵巢上皮癌

Clinical analysis of Paclitaxel liposome combined with Carboplatin in the treatment of advanced epithelial ovarian cancer

目的探讨紫杉醇脂质体联合卡铂治疗中晚期卵巢上皮癌的临床疗效及毒性。方法 35例中晚期卵巢上皮癌患者均为减瘤术后经病理学检查证实ⅡB～Ⅳ期患者。应用紫杉醇脂质体联合卡铂化疗,紫杉醇脂质体135～175mg/m2,d1,静脉滴注;卡铂剂量根据肌酐清除率计算(一般AUC=5),d2,静脉滴注;21d为1个周期,化疗2周期后评价疗效。结果 35例患者中,完全缓解4例,部分缓解22例,稳定5例,进展4例,总有效率为74.3%;患者中位疾病进展时间13.5个月,1年生存率为77.1%;毒副反应主要是骨髓抑、制恶心、呕吐、肌肉疼痛,多属Ⅰ～Ⅱ度,经对症处理后恢复。结论紫杉醇脂质体联合卡铂治疗中晚期卵巢上皮癌具有较好的近期疗效,且毒副反应可以耐受。

Objective To evaluate therapeutic effect and side effect of Paclitaxel liposome and Carboplatin in the treatment of advanced epithelial ovarian cancer.Methods 35 patients with advanced epithelial ovarian cancer were verified ⅡB～Ⅳ by cytology or pathology.35 cases were received PC chemotherapy.Paclitaxel liposome 135-175 mg/m2,d1 ivdrip.Carboplatin AUC=5 d2 ivdrip.Treatment was repeated every 21 days and the clinical response was assessed after two cycles.Results Among 35 patients,there were CR.4,PR.22,SD.5,PD.4.Total effective rate（CR＋PR）was 74.3%.Median TTP were 13.5 months.The median 1-year survival rate was 77.1%.The main side effects were bone marrow depression,nausea,vomiting and muscular soreness.But they were tolerable and degree1～2.Conclusion The treatment of Paclitaxel liposome and Carboplatin is an effective and tolerable regimen for the patient of advanced ovarian cancer.